Current Rating and Its Significance
MarketsMOJO’s 'Hold' rating for Medico Remedies Ltd indicates a cautious stance for investors. This rating suggests that while the stock may not be an immediate buy opportunity, it is not a sell candidate either. Investors are advised to maintain their current holdings and monitor the company’s performance closely. The rating was adjusted on 30 December 2025, reflecting a reassessment of the company’s prospects based on evolving market and financial conditions.
How the Stock Looks Today: Quality Assessment
As of 23 January 2026, Medico Remedies Ltd maintains a good quality grade. The company demonstrates high management efficiency, evidenced by a robust Return on Capital Employed (ROCE) of 15.04%. This figure highlights the firm’s ability to generate profits from its capital base effectively. Additionally, the company has reported positive results for the last three consecutive quarters, with a half-year ROCE peaking at 20.65% and quarterly PAT growing at an impressive 65.8%, reaching ₹2.57 crores. The debtors turnover ratio stands at a healthy 2.99 times, indicating efficient receivables management.
Valuation Perspective
Despite strong operational metrics, the stock is currently classified as expensive based on valuation parameters. The enterprise value to capital employed ratio is 5.4, which is higher than typical benchmarks, signalling a premium valuation. However, it is noteworthy that the stock trades at a discount relative to its peers’ historical averages. The company’s Price/Earnings to Growth (PEG) ratio is 0.8, suggesting that earnings growth is not fully reflected in the current price, which may offer some valuation comfort to investors.
Financial Trend and Stability
Medico Remedies Ltd’s financial trend remains positive. The company’s ability to service debt is strong, with a low Debt to EBITDA ratio of 0.89 times, indicating manageable leverage and financial stability. Over the past year, the stock has delivered a return of -32.72%, underperforming the broader market, which has generated a 7.24% return over the same period. Despite this, the company’s profits have risen by 47.8%, reflecting solid underlying business growth. This divergence between stock price and earnings growth suggests that market sentiment may be cautious or that external factors are weighing on the share price.
Technical Analysis
The technical grade for Medico Remedies Ltd is currently sideways. The stock has experienced mixed price movements recently, with a 1-day decline of 1.12%, a 1-week gain of 1.89%, but a 1-month drop of 9.53%. Over six months, the stock has rebounded with a 26.06% gain, yet the year-to-date performance remains negative at -3.84%. This sideways trend suggests a period of consolidation, where investors await clearer directional cues before committing further capital.
Additional Considerations for Investors
One factor to monitor is the reducing promoter confidence. Promoters have decreased their stake by 1.21% in the previous quarter and currently hold 61.38% of the company. Such a reduction may indicate a cautious outlook from insiders regarding the company’s near-term prospects. Investors should weigh this alongside the company’s operational strengths and valuation metrics.
Summary for Investors
In summary, Medico Remedies Ltd’s 'Hold' rating reflects a balanced view of its current position. The company exhibits strong quality and positive financial trends but faces valuation pressures and a sideways technical outlook. Investors holding the stock should continue to monitor quarterly results and market developments, while prospective investors may consider waiting for clearer signals before initiating positions.
Built for the long haul! Consecutive quarters of strong growth landed this Small Cap from Chemicals on our Reliable Performers list. Sustainable gains are clearly ahead!
- - Long-term growth stock
- - Multi-quarter performance
- - Sustainable gains ahead
Company Profile and Market Context
Medico Remedies Ltd operates within the Pharmaceuticals & Biotechnology sector and is classified as a microcap company. The sector is known for its innovation-driven growth potential but also for volatility linked to regulatory and market dynamics. The company’s current Mojo Score stands at 55.0, reflecting a moderate outlook consistent with the 'Hold' rating. This score decreased by 17 points from 72 following the rating update on 30 December 2025.
Stock Performance Overview
As of 23 January 2026, the stock’s performance has been mixed. While it has shown resilience with a 6-month gain of 26.06%, the one-year return remains negative at -32.72%. The stock’s recent price movements indicate some volatility, with a 1-month decline of 9.53% and a slight year-to-date drop of 3.84%. This performance contrasts with the broader market’s positive returns, highlighting the stock’s relative underperformance.
Investor Takeaway
For investors, the 'Hold' rating suggests maintaining existing positions while exercising caution on new investments. The company’s strong operational metrics and positive earnings growth provide a solid foundation, but valuation concerns and promoter stake reduction warrant careful monitoring. Investors should watch for upcoming quarterly results and sector developments to reassess the stock’s outlook.
Conclusion
Medico Remedies Ltd’s current 'Hold' rating by MarketsMOJO, last updated on 30 December 2025, reflects a nuanced view of the company’s prospects. As of 23 January 2026, the stock presents a blend of strong quality and financial trends tempered by valuation challenges and a sideways technical stance. This balanced assessment provides investors with a clear framework to evaluate their holdings and make informed decisions in the evolving market environment.
Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →
